The AGO3 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout pool generated from the HT29 human colorectal adenocarcinoma cell line, featuring disruption of the AGO3 gene. This genetically mixed population offers a robust loss-of-function model for investigating Argonaute 3 in colorectal cancer biology, avoiding artifacts associated with single-cell cloning. The polyclonal format preserves biological variability and facilitates large-scale functional screens, making it suitable for studying gene silencing pathways in a physiologically relevant epithelial background.
The parental HT29 cell line originated from a female colorectal adenocarcinoma and carries driver mutations in APC, TP53, BRAF (V600E), and PIK3CA. These cells maintain an epithelial phenotype and can undergo enterocytic differentiation, serving as a model for intestinal epithelial barrier function and oncogenic signaling. The concurrent activation of Wnt, MAPK/ERK, and PI3K/AKT pathways makes HT29 an ideal platform for studying miRNA-mediated regulation in cancer.
AGO3 is a core RISC protein mediating miRNA-guided gene silencing through mRNA cleavage and translational repression. It associates with TNRC6A, Dicer, TRBP, and HSP90, and is loaded with miRNAs by Dicer and Drosha. AGO3 targets transcripts including MYC, PTEN, and BCL2, influencing cell proliferation and survival. Its activity converges with oncogenic pathways hyperactivated in HT29, such as Wnt (APC/CTNNB1), MAPK (BRAF/MEK/ERK), and PI3K/AKT (PIK3CA/AKT/mTOR).
In HT29 cells, where Wnt, MAPK, and PI3K signaling are already aberrantly activated, AGO3 loss is predicted to disrupt miRNA-dependent regulation of oncogenes and tumor suppressors, potentially altering differentiation states and barrier properties. This polyclonal knockout model enables dissection of how miRNA dysregulation contributes to colorectal cancer progression and therapy resistance, providing a genetically relevant system for functional genomics studies.
Researchers can employ RNA-seq and miRNA profiling to characterize transcriptome changes, luciferase reporters to quantify miRNA activity, and co-immunoprecipitation to analyze RISC composition. Phenotypic assays such as MTT proliferation, apoptosis detection, and migration/invasion studies link AGO3 loss to cellular behavior. Drug sensitivity testing may uncover miRNA-dependent chemoresistance, while differentiation assays explore AGO3??s role in enterocytic maturation. For additional information, please contact Ascent Research.
